Close Menu

Share with your friends

Close

Creso Pharma (ASX: CPH)

Creso Pharma (ASX: CPH) has become the first ASX listed company to import medicinal cannabis products into Australia under new government legislation, as it looks to capitalize on growing interest and demand.

CPH’s ability to distribute Canadian partner CanniMed®’s products across Australia in authorized pharmacies, via its Australian distributor Health House International, gives the company a big head start and a first mover advantage over other companies in this space.

And with $10.6 million cash at end of last quarter and products at the ready, CPH will look to fast track Australian market penetration, whilst keeping an eye on its global ambitions.

Helping CPH’s push will be newly appointed COO David Russell, a highly experienced pharmaceutical and biotech industry stalwart, who has more than 25 years’ experience with a number of leading global billion dollar companies including Roche, Actelion Pharmaceuticals, Celgene and Novogen.

Mr Russell will provide invaluable insight and direction into go-to-market strategies for CPH and will also be responsible for developing the Australian business and overall commercial strategy for CPH in Australia.

The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

CPH is full steam ahead as it looks for global distribution channels for an active pipeline of products, concentrating both on animal health and on the human health markets.

Having a first mover product advantage in Australia is just one more step in the company’s journey for global medicinal cannabis dominance.

 

Latest Article

CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release

News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.

Jun 14, 2017 Continue Reading

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.